PEOPLE - Ceapro makes appointment:
This article was originally published in Clinica
Executive Summary
Edmonton, Alberta-based Ceapro has appointed Oleh Hnatiuk as acting managing director of its Ceapro Technology subsidiary. He will have supervision of the commercial activities relating to AccuScreen, the group's type 2 diabetes early detection test. Mr Hnatiuk is president of technology commercialisation advisory company Connect Capital Corp and was formerly president of University Technologies International. His skills and experience in networking will be employed at a critical time for the commercial introduction of AccuScreen, said Ceapro president and CEO Dr Mark Redmond.